Implantica
Tracked across 2 events · 38 articles · First seen Aug 14, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Implantica is the company hosting the Q2 2026 earnings presentation. The event provides an opportunity for the company to communicate its financial results and strategic progress to investors.
Aug 14, 2026 · 6 articles
Regulatory
Implantica AG, a Liechtenstein-based medtech company, received Premarket Approval (PMA) from the U.S. United States — Food and Drug Administration (FDA) for its RefluxStop device, an implantable treatment for gastroesophageal reflux disease (GERD). The approval,…
Impact: Implantica is the central company receiving FDA approval for its lead product RefluxStop, enabling U.S. market entry and representing a major growth milestone.
Aug 20, 2026 · 32 articles
100
United States — Food and Drug Administration granted premarket approval ImplanticaImplantica Receives FDA...
80
Implantica reportedImplantica Receives FDA...
70
Implantica expanded United StatesImplantica Receives FDA...
70
Implantica announcedImplantica Receives FDA...
50
Implantica expanded SpainImplantica Receives FDA...
Peter Forsell
ceo and founder
↔
Implantica
Peter Forsell is the founder and current CEO of Implantica, a medical technology
ERGEN INTELLIGENCE
Track Implantica live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard